Literature DB >> 15016558

A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure.

Neil Choplin1, Paula Bernstein, Amy L Batoosingh, Scott M Whitcup.   

Abstract

In glaucoma and ocular hypertension, clinically relevant intraocular pressure lowering due to a new medication is frequently defined as at least a 15% or 20% reduction from baseline intraocular pressure. This report compares the percentages of treated patients achieving such reductions in intraocular pressure after 6 months of treatment with bimatoprost or latanoprost. In the previously published study (Noecker et al: A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 135:55-63, 2003), patients with glaucoma or ocular hypertension were randomly assigned to once-daily treatment with bimatoprost 0.03% (n=133) or latanoprost 0.005% (n=136), after washout of any previous glaucoma medications. The primary outcome measure of that study was mean change from baseline intraocular pressure. The secondary, post hoc analysis presented here compares the diurnal and long-term responder rates observed with bimatoprost and latanoprost patients. Diurnal responders were defined as patients who achieved at least a 15% or 20% reduction from baseline intraocular pressure at each of the three timepoints (8 am, 12 pm, and 4 pm) on a given visit. At week 1 and months 1, 3, and 6, in the bimatoprost group, 70.7-81.2% of patients achieved at least a 15% reduction in IOP at each timepoint, and 57.9-68.4% achieved at least a 20% reduction. Significantly fewer patients receiving latanoprost achieved a 15% or a 20% decrease in IOP at each timepoint: 48.5-61.8% of patients achieved at least a 15% decrease and 36.0-47.1% achieved at least a 20% decrease. (P< or =.007). The data presented here suggest that patients using bimatoprost are more likely than patients using latanoprost to achieve intraocular pressure reductions of at least 15% or 20% from baseline throughout the day.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15016558     DOI: 10.1016/j.survophthal.2003.12.016

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  5 in total

Review 1.  Effects of prostaglandin analogues on aqueous humor outflow pathways.

Authors:  Nelson S Winkler; Michael P Fautsch
Journal:  J Ocul Pharmacol Ther       Date:  2013-12-20       Impact factor: 2.671

2.  Effect of prostaglandin analogs: Latanoprost, bimatoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human trabecular meshwork endothelial cells.

Authors:  Jae Young Heo; Yen Hoong Ooi; Douglas J Rhee
Journal:  Exp Eye Res       Date:  2020-03-25       Impact factor: 3.467

Review 3.  Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension.

Authors:  Masato Matsuo; Yotaro Matsuoka; Masaki Tanito
Journal:  Clin Ophthalmol       Date:  2022-04-26

Review 4.  Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG/OHT Patients.

Authors:  Ziyan Cai; Mengdan Cao; Ke Liu; Xuanchu Duan
Journal:  J Ophthalmol       Date:  2021-05-25       Impact factor: 1.909

5.  Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study).

Authors:  Makoto Aihara; Fenghe Lu; Hisashi Kawata; Yuki Tanaka; Kenzo Yamamura; Noriko Odani-Kawabata; Naveed K Shams
Journal:  J Ocul Pharmacol Ther       Date:  2019-11-01       Impact factor: 2.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.